Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

immunotherapy

- PMLiVE

EU fast-tracks review of Pfizer/BioNTech COVID-19 vaccine

CHMP meeting scheduled for 21 December

- PMLiVE

Boehringer spends €1.18bn to acquire NBE-Therapeutics

Company specialises in antibody-drug conjugate development

EU flag

EU buys 160 million doses of Moderna’s COVID-19 vaccine

Deal follows positive data readout last week

Roche Basel Switzerland

Roche’s Xofluza pill wins FDA approval for post-exposure flu prevention

First single-dose flu medication approved for post-exposure prophylaxis

Sanofi reception

Sanofi’s quadrivalent flu vaccine Supemtek scores EU approval

Company expects first EU launches in 2022/2023 flu season

Roche Basel Switzerland

Roche’s flu pill Xofluza moves closer towards EU approval

CHMP recommends drug for approval in the EU

- PMLiVE

EU secures 405 million doses of CureVac’s COVID-19 vaccine

CureVac revealed early stage data for its vaccine earlier this month

EU flag

EU agrees on supply deal for 200 million doses of Pfizer, BioNTech’s COVID-19 vaccine

European Commission will have an option to request another 100 million doses

- PMLiVE

Moderna posts encouraging early data for personalised cancer vaccine

Vaccine tested alongside Merck's Keytruda

- PMLiVE

Merck strengthens oncology pipeline with $2.75bn VelosBio deal

The deal will give Merck control of VLS-101, an antibody-drug conjugate

- PMLiVE

Sanofi set to acquire Kiadis for €308m

Acquisition will see French pharma gain access to NK-cell platform

- PMLiVE

Roche and Atea link up for oral COVID-19 drug; UK to test coronavirus vaccine T cell responses

New developments for COVID-19 treatments and vaccines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links